Furthermore, an aldosterone receptor antagonist indirectly upregulates IL-33 expression by reducing ST2 levels, enhancing the IL-33/ST2 signaling pathway and then reducing inflammation and fibrosis after MI [25]. This evidence concerns the gene IL33 and myocardial infarction.